

INSTITUTIONAL BIOSAFETY COMMITTEE MEETING DRAFT MINUTES

The University of Texas at San Antonio
Wednesday August 5, 2026
Microsoft Teams Meeting

Minutes Prepared by: Ashok Chaturvedi

MEMBERS PRESENT (7 needed for quorum)

- ☒ Dr. Jose Lopez-Ribot, Chair, Voting
- ☒ Dr. Janakiram Seshu, Vice-Chair, Voting
- ☒ Dr. JiehJuen Yu, Voting
- ☐ Dr. Karl Klose, Voting
- ☐ Dr. Marcel Perret-Gentil, Voting
- ☒ Dr. Jurgen Engelberth, Voting, Plant Specialist
- ☒ Dr. Astrid Cardona, Voting
- ☐ Mr. Rich Garza, Asst. Director Laboratory Safety & Hazardous Materials Management with vote
- ☒ Ms. Yolanda Acosta, *ex officio* Scientific Alternate with vote
- ☐ Dr. Ana Vallor, Non-Affiliated, Voting
- ☐ Dr. Shannan Hall-Ursone, Non-Affiliated, Voting
- ☐ Mr. Anthony Vallejo, *ex officio*, Director of Laboratory Safety, (Scientific Alternate)
- ☒ Dr. Ashok Chaturvedi, *ex officio*, Biological Safety Manager, (Scientific Alternate)

GUESTS

- ☒ Mrs. Rachel Davis, UTSA Scholarly Resources Librarian
- ☐ Ms. Jolyn Demarest, Occupational Health Program non-voting
- ☐ Dr. Hamid Badali, Voting, (Scientific Alternate)
- ☒ Ms. Yulissa Stevens, Laboratory Safety Specialist non-voting

START: 9:00 AM

ADJOURN: 9:40 AM

7 voting members present

I. Review of the Minutes of the Previous IBC Meeting

Review of the July 1st Minutes – Approved

Committee Decision: 7 in favor, 0 opposed, and 0 abstention

II. Review of New or Renewal Applications

In reviewing each protocol discussed below, the committee gave consideration to the following specific concerns, as appropriate:

- a. Adequacy of containment equipment / procedures / facilities to be implemented
- b. Agent characteristics (e.g., virulence, pathogenicity, environmental stability)
- c. Types of manipulations planned
- d. Source(s) of the inserted DNA sequences (e.g., species)
- e. Nature of the inserted DNA sequences (e.g., structural gene, oncogene)
- f. Host(s) and vector(s) to be used
- g. Whether or not an attempt will be made to obtain expression of a foreign gene, and if so, the protein that will be produced.

IBC# 2087 Investigating the function, connectivity, and plasticity of peripheral sensory circuits

Project Overview

Microbial Agents, Infectious Agents or Toxins
E. Coli, rAAV
Biosafety Level
BSL-2
Risk Group
RG 1
Section of the NIH Guidelines (if applicable)
Sections III-D, IIID-4, IIID-4a, IIIE-1 and Appendix B-1

Principal Investigator

Lindsey Macpherson

Committee Decision: 7 in favor, 0 opposed, and 0 abstention**Score:** 01**IBC# 2097 Investigations into embryonic germ cell development.****Project Overview**

Microbial Agents, Infectious Agents or Toxins
5-alpha Competent E. Coli
Biosafety Level
BSL-2
Risk Group
RG 1
Section of the NIH Guidelines (if applicable)
III-D-4-a ; III-E-3-a (use, not generation and no live rodents will ever be in this lab space, so i'm not sure this last one applies)
Principal Investigator
Lacy Barton

Score: 02**Committee Decision:** 7 in favor, 0 opposed, and 0 abstention**IBC# 2099 Neuromodulation of the central auditory pathway****Project Overview**

Microbial Agents, Infectious Agents or Toxins
rAAV, Tetrodotoxin (TTX)
Biosafety Level
BSL-2
Risk Group
Section of the NIH Guidelines (if applicable)
rDNA/SNA work in one or more of the following NIH Guidelines exempt categories: Section III-F-1; Section III-F-2; Section III-F-3; Section III-F-4; Section III-F-5; Section III-F-6, Appendices A-I through A-VI; Section III-F-7.
Principal Investigator
Marina Silveira

Score: 01

Committee Decision: 7 in favor, 0 opposed, and 0 abstention

III. Review of Amendments

In reviewing each protocol discussed below, the committee gave consideration to the following specific concerns, as appropriate:

- a. Adequacy of containment equipment / procedures / facilities to be implemented
- b. Agent characteristics (e.g., virulence, pathogenicity, environmental stability)
- c. Types of manipulations planned
- d. Source(s) of the inserted DNA sequences (e.g., species)
- e. Nature of the inserted DNA sequences (e.g., structural gene, oncogene)
- f. Host(s) and vector(s) to be used
- g. Whether or not an attempt will be made to obtain expression of a foreign gene, and if so, the protein that will be produced.

IBC#49

Project Overview

S/N	Lab Name	PI	Amendments	Reviewer comments	Decision
1	Immunology Teaching Labs	Ana Chamoun-Emanuelli	IBC# 49 Immunology Teaching Lab	N/A	

Score 1

Committee Decision: 0 in favor, 0 opposed, and 0 abstention

IV. Administrative Approvals

S/N	Lab Name	Title	Reviewer comments	Decision
1	Silveira Lab	IBC#2099 Neuromodulation of the central auditory pathway	N/A	IBC Chair approved 08/14/2026
2	Macpherson Lab	IBC# 2087 Investigating the function, connectivity, and plasticity of peripheral sensory circuits	N/A	IBC Chair approved 08/14/2026

3	Immunology Teaching Labs	IBC#49 Immunology Teaching Lab	N/A	IBC Chair approved 08/21/2026
---	--------------------------	--------------------------------	-----	----------------------------------

V. Expired / Closed Protocols


None at this time.

VI. New Business

A. None at this time.

VII. Adjourn

The meeting was adjourned at 9:40 a.m. Next meeting will take place on Wednesday, September 02, 2026, at 9:00 am via Teams.



X _____

Jose Lopez-Ribot
IBC Chair